Goldman Sachs analyst Stephen Tanal upgraded UnitedHealth to Conviction Buy from Buy with a price target of $330, up from $300. With an attractive commercial business, the number one market share position in Medicare Advantage and a top three position in Medicaid, UnitedHealthcare is "uniquely well-positioned" to utilize the services of Optum, Tanal tells investors in a research note. Over $19B of operating cash flow in 2020 will "handily cover" the company's $2.3B of capital expenditures, leaving the company well positioned to deploy capital against earnings growth via tuck-in acquisitions and share repurchases, adds the analyst.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here